Sugentech Inc. (KOSDAQ:253840)

Market Cap	89.29B +12.5%
Revenue (ttm)	9.42B -6.7%
Net Income	-23.31B
EPS	-1,525.00
Shares Out	15.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	751,746
Average Volume	2,631,966
Open	5,910.00
Previous Close	5,930.00
Day's Range	5,830.00 - 6,190.00
52-Week Range	4,310.00 - 9,390.00
Beta	0.55
RSI	57.81
Earnings Date	May 14, 2026

About Sugentech

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was ...

• Industry: Medical - Specialties
• Sector: Healthcare
• Founded: 2011
• Employees: 144
• Stock Exchange: KOSDAQ
• Ticker Symbol: 253840

Financial Performance

In 2025, Sugentech's revenue was 9.42 billion, a decrease of -6.74% compared to the previous year's 10.10 billion. Losses were -23.31 billion, 53.5% more than in 2024.